查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球去势抵抗性前列腺癌治疗市场
市场调查报告书
商品编码
1140679

2022-2029 年全球去势抵抗性前列腺癌治疗市场

Global Castrate Resistant Prostate Cancer Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

前列腺癌患病率上升导致市场增长。

全球前列腺癌患病率的上升正在刺激前列腺癌药物的市场增长。前列腺癌是男性最常见的癌症，除了皮肤癌。根据 Cancer.Net 编辑委员会的估计数据，2022 年美国将有 268,490 名男性被诊断出患有前列腺癌。网络编辑委员会估计显示，2020 年将有 1,414,259 名男性被诊断出患有前列腺癌。它是世界上第四大最常见的癌症。它是美国男性癌症死亡的第二大原因。 2020年将有34,500人死于前列腺癌，全球将有375,304人死于前列腺癌。发达国家的前列腺癌患病率高于发展中国家。癌症患者数量的增加将导致对去势抵抗性前列腺癌药物的需求增加，以最大限度地降低死亡风险并减少病毒对肿瘤的影响。全球市场的消费者俱有健康意识，愿意花大价钱改善严重的健康状况。在预测期内，消费者平均消费能力的提高和癌症患病率的上升将推动全球对去势抵抗性前列腺癌治疗的需求。

几种针对去势抵抗性前列腺癌的药物获批将有助于市场增长。政府对去势抵抗性前列腺癌药物营销的关注在世界范围内显着增加。最近的几项发展突出了去势抵抗性前列腺癌治疗市场，包括： 2022 年 3 月，FDA 批准 Pullvict 用于通过雄激素受体（ AR ）通路阻断和紫杉烷化疗治疗的转移性去势抵抗性前列腺癌。

然而，与去势抵抗性前列腺癌治疗相关的高成本将成为预测期内市场增长的主要抑制因素。

地理渗透。

北美是预测期内的主要地区。

2019年，全球去势抵抗性前列腺癌治疗市场以市场份额最大的北美市场为主。推动北美市场增长的因素包括前列腺癌发病率和患病率的显着增加以及提高对前列腺癌认识的举措。例如，美国和加拿大每年 9 月都会庆祝前列腺癌宣传月。该组织还为前列腺癌研究提供资助。

此外，预计亚太地区将以全球市场最高的复合年增长率增长。这是由于该地区前列腺癌的高发病率以及中国和印度等主要经济体迅速发展的医疗基础设施，推动了前列腺癌药物市场的增长。

竞争格局。

去势抵抗性前列腺癌治疗市场由少数公司主导。主要的市场增长参与者包括 Astellas Pharma、Bayer AG、Johnson & Johnson Services、辉瑞、Sanofi SA、GlaxoSmithKline PLC、Northwest BioTherapy 和 Active Biotech AB。预计主要参与者将执行多项增长战略，例如产品发布、收购和合作伙伴关係，这些战略预计将促进全球去势抵抗性前列腺癌治疗市场的增长。 2020年5月，XTANDI获日本厚生劳动省批准用于治疗远处转移的前列腺癌。 XTANDI 是一种口服雄激素受体信号抑製剂，适用于治疗转移性前列腺癌患者。 2022 年 8 月，FDA 批准买方的前列腺癌药物扩大使用。该批准基于 ARASENS 3 期试验的结果，该试验表明，与 ADT 和多西他赛相比，Nubeqa 与雄激素剥夺疗法和多西他赛相结合可将死于前列腺癌的风险降低多达 32%。一些大公司遵循收购战略来扩大业务。例如，2021 年 6 月，拜耳收购了 Noria 和 PSMA Therapeutics，以扩大其前列腺癌管道。通过此次收购，买方拥有基于actinium-225和前列腺特异性膜抗原（PSMA）小分子的差异化α-放射性核素研究化合物的独家权利。

COVID-19 的影响将对全球去势抵抗性前列腺癌治疗市场产生负面影响。

COVID-19 的爆发预计将减缓 2020 年去势抵抗性前列腺癌治疗市场的增长。由于医院就诊次数减少导致的诊断率下降是对 2020 年去势抵抗性前列腺癌治疗市场增长产生负面影响的主要因素。

内容

第 1 章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按治疗类型划分的市场细分
  • 按给药方式划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 促进因素
      • 去势抵抗性前列腺癌的患病率不断上升
      • 医疗保健支出增加
    • 抑制因素
      • 缺乏标准治疗
    • 商机
    • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 价值链分析
  • PEST 分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按治疗类型

  • 化疗
  • 激素疗法
  • 免疫疗法
  • 放射治疗

第 8 章给药方式

  • 口服
  • 注入

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 市场定位/市场份额分析
  • 併购分析

第 11 章公司简介

  • Astellas Pharma, Inc.
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Sanofi SA
  • GlaxoSmithKline PLC
  • Northwest Biotherapeutic
  • Active Biotech AB
  • Spectrum Pharmaceuticals
  • Abbott Laboratories
  • Other Companies（*LIST NOT EXHAUSTIVE）

第 12 章 DataM

简介目录
Product Code: DMHCIT2977

Market Overview

Castrate Resistant Prostate Cancer Therapeutics Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 8.4% during the forecast period (2022-2029).

Castration-resistant prostate cancer is stated as prostate cancer that is scattered to other parts of the body. Several risk factors for castration-resistant prostate cancer include genetic predisposition, unhygienic diet, geriatric population, medication exposure, and many sexual partners. The methods were available to diagnose castration-resistant prostate cancer, including prostate imaging, tumor marker, biopsy, and staging test. For CRPC treatment, docetaxel-based chemotherapy has been widely accepted by urologists and oncologists. The increasing prevalence of prostate cancer, including castration-resistant prostate cancer, augments the market growth. Moreover, the increasing geriatric population is the main driver of the market.

Market Dynamics: The growing prevalence of prostate cancer leads to the market's growth.

The rising incidences of prostate cancer globally are spurring the market growth for prostate cancer therapeutics. Prostate cancer is most common in men, except for skin cancer. According to the data estimated by the Cancer.Net Editorial Board, 268,490 men in the United States were diagnosed with prostate cancer in 2022. According to Net Editorial Board, estimated data of 1,414,259 people were diagnosed with prostate cancer in 2020. It is the fourth most commonly diagnosed cancer in the world. It is the second leading cause of cancer death in men in the United States. There were 34,500 people who died of prostate cancer in 2020, and 375,304 people worldwide died of prostate cancer. Developed nations have a higher prevalence of prostate cancer cases than developing nations. Cancer patients' growth leads to increased demand for castrate-resistant prostate cancer therapeutics to minimize the risk of death and lower the virus's effect on the tumor. The global market consumers are highly health-conscious and ready to spend high amounts to enhance their severe health conditions. The growth in the consumers' average purchasing power and rising cancer prevalence will fuel the demand for castrate-resistant prostate cancer therapeutics globally during the forecast period.

Several drug approvals for castrate-resistant prostate cancer help to grow market growth. The government's focus on marketing castrate-resistant prostate cancer therapeutics is increasing considerably across the globe. There are several recent developments noticed in the castrate-resistant prostate cancer therapeutics market, such as. In March 2022, the FDA approved Pluvicto for metastatic castration-resistant prostate cancer treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

However, the high cost associated with castrate-resistant prostate cancer treatment is the major restraint for the market's growth during the forecast period.

Market Segmentation: The oral drug delivery segment accounted for the highest share in global castrate resistant prostate cancer therapeutics market.

The castrate-resistant prostate cancer therapeutics market is classified into oral drug delivery methods and injectable drug delivery methods by drug delivery method. The oral drug delivery method contributes a major share of the castrate-resistant prostate cancer therapeutics market. The doctors majorly suggest oral medicines compared to injectables for the treatment of castrate-resistant prostate cancer. The market players have also engaged in marketing oral castrate-resistant prostate cancer therapeutics across the globe.

By therapy type, the castrate-resistant prostate cancer therapeutics market is classified into chemotherapy, hormonal therapy, immunotherapy, and radiotherapy. The hormonal therapy segment held a significant share in the market. Hormone therapy is often regarded as an androgen suppression therapy. The therapy aims to block or lower testosterone in the body to stop it from fueling prostate cancer cells' growth. Lowering androgen levels often makes prostate cancers grow sluggish. Based on drugs' functioning, hormonal therapy is of different types that include orchiectomy and medical castration. Medical castration involves the luteinizing hormone-releasing hormone (LHRH) agonist drugs that lower the amount of testosterone made by the testicles. Leuprolide, Goserelin, Triptorelin, and Histrelin are the commonly used LHRH agonist drugs available in the US market.

Geographical Penetration: North America is the dominating region during the forecast period.

The North American market dominated with the largest market share in the global castrate-resistant prostate cancer therapeutics market in 2019. Factors augmenting the North American market's growth include a significant rise in the incidence and prevalence of prostate cancer and initiatives to create awareness for prostate cancer. For instance, Prostate Cancer Awareness Month is observed in the US and Canada in September every year. Also, the organizations offer grants for prostate cancer research.

Moreover, the Asia Pacific region is expected to grow at the highest CAGR in the global market owing to the high prevalence of prostate cancer in the region coupled with the rapidly evolving healthcare infrastructure in major economies such as China and India are fueling the growth of the castrate-resistant prostate cancer therapeutics market.

Competitive Landscape:

The castrate-resistant prostate cancer therapeutics market is dominated by a few companies. Some of the key players in the market's growth include Astellas Pharma, Inc., Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., Sanofi SA, GlaxoSmithKline PLC, Northwest Biotherapeutic, and Active Biotech AB, among others. The key players execute several growth strategies, such as product launches, acquisitions, and collaborations, which are estimated to boost the castrate-resistant prostate cancer therapeutics market growth globally. In May 2020, XTANDI was approved by the Japan Ministry of Health, Labour and Welfare (MHLW), which is used for the treatment of prostate cancer with distant metastasis. XTANDI is the oral androgen receptor signaling inhibitor for the treatment of prostate cancer patients with distant metastasis. In August 2022, FDA approved the expanded use of Buyer's prostate cancer drug. This approval is based on the results of Phase 3 ARASENS trial, which demonstrated a reduction in the risk of death by prostate cancer up to 32% in Nubeqa plus androgen deprivation therapy and docetaxel compared to ADT and docetaxel. Some major players follow acquisition strategies to expand their business. For instance, in June 2021, Bayer Acquired Noria and PSMA Therapeutics to expand its pipeline in prostate cancer. Through this acquisition, the Buyer obtained exclusive rights to a differentiated alpha radionuclide investigational compound based on actinium-225 and a small molecule directed towards prostate-specific membrane antigen (PSMA).

COVID-19 Impact: Negative impact on the global castrate resistant prostate cancer therapeutics market.

The COVID-19 pandemic outbreak is expected to derail the growth of the castrate-resistant prostate cancer therapeutics market in 2020. The decline in the diagnosis rate due to the downfall in the number of hospital visits is the major factor that has negatively impacted the castrate-resistant prostate cancer therapeutics market growth in 2020.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Therapy Type
  • 3.2. Market Snippet by Drug Delivery Method
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising prevalence of castrate-resistant prostate cancer
      • 4.1.1.2. Increasing spending on healthcare
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of standard therapy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Therapy Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type Segment.
  • 7.3. Market Attractiveness Index, By Therapy Type Segment
    • 7.3.1. Chemotherapy
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Hormonal Therapy
    • 7.3.3. Immunotherapy
    • 7.3.4. Radiotherapy

8. By Drug Delivery Method

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method Segment.
  • 8.3. Market Attractiveness Index, By Drug Delivery Method Segment
    • 8.3.1. Oral
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Injectable

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. The U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. The U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. The Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Astellas Pharma, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Bayer AG
  • 11.3. Johnson & Johnson Services Inc.
  • 11.4. Pfizer Inc.
  • 11.5. Sanofi SA
  • 11.6. GlaxoSmithKline PLC
  • 11.7. Northwest Biotherapeutic
  • 11.8. Active Biotech AB
  • 11.9. Spectrum Pharmaceuticals
  • 11.10. Abbott Laboratories
  • 11.11. Other Companies(*LIST NOT EXHAUSTIVE)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us